🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the battle against increasingly resistant strains of the infection, according to health experts.

A Global Health Concern

Gonorrhoea infections are on the rise globally, with figures suggesting in excess of 82 million new cases per year. Notably increased rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the context of rising global incidence, escalating drug resistance and the very limited therapeutic options currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The WHO has designated it as a "critical concern". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers hope that specific application of this new drug will help delay the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, was also approved in concurrent days. This drug, which is employed against urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for drug creation. The non-profit organisation GARDP collaborated with the drug firm Innoviva to see it through.

“This authorization signifies a significant shift in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Results and Global Access

According to findings detailed in a major medical journal, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which uses two antibiotics. The trial involved over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have voiced optimism. Having a single-dose, oral treatment such as this is seen as a "critical tool" for public health efforts. This is viewed as crucial to alleviate the strain of the infection for patients and to stop the proliferation of untreatable gonorrhoea globally.